Cached score snapshot

US.WST · West Pharmaceutical Services

110分制 59.9/110;5D動能v2 9/50;排序分 68.9/160 · Incomplete inputs

Ranking score 68.9/160
Main score 59.9/110
5D momentum v2 9/50
Rank #118
Setup grade B 68.2

Score breakdown

觀望

Medium twelvedata

Score and price trend

B 68.2 Money flow A · lift 1.36x

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 07-31 09-02 10-06 11-06 12-04 $324.92$376.18$427.45 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.484 · anchors 120 +0.79% -0.80% / +3.40% 65% 0% Actual outcome pending · 1 / 3 bars observed
30D observation -0.71% -5.12% / +1.17% 42.5% 25% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +0.40% -1.71% / +2.47% 56.3% 3.1% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。

2026-07-31 → 2026-12-04 · 90 archived points · 4 Improving turn signal · 8 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 68.9
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 59.9/110 (觀望)
5D momentum v2 9/50 (弱)
Score with momentum v2 68.9/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分,但以下輸入仍不完整;缺失維度以 0 分處理,請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 376.582
ma50 362.0668
close 392.15
prevClose 394.03
avgVolume20 513335
volumeRatio 1.4
changePercent -0.48

Metrics snapshot

close 392.15
volume 718000
changePercent -0.48

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 59.9/110
Main rating 觀望
5D momentum v2 9/50
Score with momentum v2 68.9/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 3.2/5 · 一般

Dimension score 3.2/5
Dimension grade 一般

Sub-items

pbPoints 0.2
pePoints 0.2
epsPoints 0
roePoints 0.6
debtPoints 0.5
marginPoints 0.4
turnoverUsdM 281.5637
volumePoints 0.5
revenuePoints 0
dividendPoints 0.3
marketCapPoints 0.5

資金流 — 15.6/20 · 良好

Dimension score 15.6/20
Dimension grade 良好

Sub-items

cmfPoints 1.6
mfiPoints 4
obvPoints 4
vwapPoints 4

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.WST
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 4.6/15 · 較差

Dimension score 4.6/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 0.8

details

qqq

ma20 735.235
ma50 725.8122
name QQQ
close 704.4
points 0.4

spy

ma20 770.1505
ma50 767.8084
name SPY
close 759.97
points 0.4
source twelvedata+fred
atrPct 2.1489
atrPoints 3
cciPoints 0.8
vixPoints 0
marketTrendPoints 0.8

催化劑 — 2/20 · 較差

Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 2
catalystCount 0
catalystPoints 2

風險管理 — 7.8/10 · 良好

Dimension score 7.8/10
Dimension grade 良好

Sub-items

position

score 1.6

details

atrPct 2.1489
turnoverUsdM 281.5637
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.8

stopLevels

symbol US.WST
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 375.2958

strength_details

ma_score 1.5
atr_score 2
rsi_score 3
macd_score 3
volume_score 2
market_adjustment 1
risk_reward_ratio 1.7
stop_loss_percent 4.3
take_profit_price 421.1954
target_multiplier 2.2
technical_strength 2.35
take_profit_percent 7.4
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.7218
stopLossPercent 4.2979
diversificationPoints 2

技術信號 — 20.7/30 · 一般

Dimension score 20.7/30
Dimension grade 一般

Sub-items

bbPoints 3
adxPoints 3
sarPoints 2.4
vcpPoints 0.4
macdPoints 4

vcpPayload

vcp_pass false
vcp_score 0.4
vcp_reason 站上MA50;Ready=N;Confirm=N

vcp_metrics

up_days 8
vol_ref 583796.6667
down_days 1
vcp_ready false
above_ma50 true
avg_vol_10 482740
avg_vol_20 499135
avg_vol_30 583796.6667
range_pct_10 0.0892
range_pct_20 0.0961
range_pct_30 0.1415
up_expand_ok false
lookback_used 59
near_20d_high true
contraction_ok false
down_shrink_ok false
up_expand_days 1
breakout_20d_ok false
vol_ratio_10_30 0.8269
dist_to_20d_high 0.0126
down_shrink_days 1
breakout_level_20d 397.16
vcp_breakout_confirm false
contraction_ratio_10_30 0.6305
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.7
rsiKdjPoints 3.2
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0.8
shortMacdPoints 0.4
volConfirmPoints 0
volumePointsTechnical 1.2

情緒分析 — 6/10 · 一般

Dimension score 6/10
Dimension grade 一般

Sub-items

sentiment

score 6

details

source finnhub_news_keyword_model
articleCount 2
negativeHits 0
positiveHits 1
sentimentScoreRaw 1.2

sentimentData

raw {"id":142704930,"url":"https://finnhub.io/api/news?id=396ce0c5d19d15c2565049240f584d084b0c576b95a0294c7aeb9e87bd960d54","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services has seen its share price climb sharply in recent periods, and that kind of run naturally raises a question for anyone looking at the stock today: Are the cash flows the business can generate over time enough to support where the market is currently pricing West Pharmaceutical Services? The share price has gained 37.2% over the past year, which puts a lot of weight on whether the underlying cash flows can keep backing up that move. The group’s role in supplying...","category":"company","datetime":1791418604,"headline":"West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short"}, {"id":142563086,"url":"https://finnhub.io/api/news?id=9fe356bb8b6c323b81461cdff686ec1dca817daefb117d2d9a070c3e2998bf36","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at West Pharmaceutical Services (NYSE:WST) and the best and worst performers in the drug development inputs & services industry.","category":"company","datetime":1790884627,"headline":"Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)"}
raw_source {"id":143012560,"url":"https://finnhub.io/api/news?id=2ccb53addaa9d01eacfe7687646e84a97e6ee4cf6e4a9eac5b9b5469477a9e02","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"On October 19, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared a fourth-quarter dividend of $0.26 per share on the Company's common stock, an 18% increase over the $0.22 per share paid in the prior quarter. This is the thirty-fourth consecutive annual increase in the Company's dividend. The dividend is payable on November 18, 2026, to shareholders of record on November 11, 2026.","category":"company","datetime":1792447440,"headline":"West Declares Quarterly Dividend"}, {"id":143025098,"url":"https://finnhub.io/api/news?id=184da90b2ecaa23ac41e65cf4a68ca4e56b6205b3de07c9de99399644af7a9b5","image":"https://cdn.benzinga.com/files/images/story/2026/10/19/Monticello---Circa-June-2018-Ball-Corpor.jpg?width=2048&height=1536","source":"Benzinga","related":"WST","summary":"Ball Corp stock is on an 11-day winning streak, its longest since NYSE trading began in 1973, while the S&P 500 has slipped. Here is what the data shows.","category":"company","datetime":1792422605,"headline":"This 146-Old Can Maker Is On a Winning Streak Unseen In Its Half-Century Stock History"}, {"id":143000911,"url":"https://finnhub.io/api/news?id=9f249892f67c2c347a5af48c3b7f211933f468a1f63145c7891bc123511d8112","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.","category":"company","datetime":1792402615,"headline":"3 Low-Volatility Stocks We’re Skeptical Of"}, {"id":142916913,"url":"https://finnhub.io/api/news?id=e43427db7a051fa81b2854dcfd0b6bd24d6b41b26470c7092a985c1c34b6620a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical shares have surged 36.1% YTD, fueled by strong demand for high-value components, earnings momentum and raised guidance. Can the rally continue?","category":"company","datetime":1792067100,"headline":"West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?"}, {"id":142883145,"url":"https://finnhub.io/api/news?id=cb38b4a6f60d1666f4829b94ca34f67fc98bf5704a46799c99024c3bf926f5dd","image":"https://cdn.benzinga.com/files/images/story/2026/10/14/Experts-Stress-Individual-Strategy.jpg?width=2048&height=1536","source":"Benzinga","related":"WST","summary":"CNBC traders picked WST, JPM, META and IYE; analysts raised WST and META targets, while JPM missed Q3 earnings and revenue estimates.","category":"company","datetime":1791965393,"headline":"Meta, JPMorgan, West Pharmaceutical And More: CNBC’s ‘Final Trades’"}, {"id":142851461,"url":"https://finnhub.io/api/news?id=01a6d2c9516083848f4715e79557defa90311fe00d1d962ba8800ec121c82bee","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"VEEV's push into early-stage biotech could unlock long-term revenue opportunities as its streamlined software solutions simplify critical drug development processes.","category":"company","datetime":1791900180,"headline":"Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms"}, {"id":142852015,"url":"https://finnhub.io/api/news?id=5c93e86e39a831dabc1abec85f4b6dda5ce3762aebf201f5f36fbb96e9de0f04","image":"https://image.cnbcfm.com/api/v1/image/108404206-17919110711791911068-48976902142-1080pnbcnews.jpg?v=1791911070&w=1920&h=1080","source":"CNBC","related":"WST","summary":"The Investment Committee gives you their top stocks to watch for the second half.","category":"company","datetime":1791897084,"headline":"Final Trades: JP Morgan, Meta, West Pharmaceutical Services and the iShares U.S. Energy ETF"}, {"id":140020268,"url":"https://finnhub.io/api/news?id=4f3164aa80c98143908bac684d9370239ee6fc0adb34291736a50ae401f2fc06","image":"","source":"Benzinga","related":"WST","summary":"","category":"company","datetime":1791896442,"headline":"Inexpensive Stocks Found In This Sector"}, {"id":142883147,"url":"https://finnhub.io/api/news?id=64790aefb0dca839b96e5a83d13b90b9b8a6e2684e44515eb2c3a5b6bcb1f488","image":"","source":"Benzinga","related":"WST","summary":"TD Cowen analyst Brendan Smith maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $410 to $420.","category":"company","datetime":1791895217,"headline":"TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $420"}, {"id":142806662,"url":"https://finnhub.io/api/news?id=88a74baf83fffd8b419bb6c42be37ea4daa59b2aa69282ceb6e60f787cf3393b","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2252678669/image_2252678669.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"WST","summary":"Track 50 top dividend growth stocks: AMAT, DHI & HD climb as valuations shift.","category":"company","datetime":1791722816,"headline":"Top 50 High-Quality Dividend Growth Stocks For October 2026"}, {"id":142764350,"url":"https://finnhub.io/api/news?id=2e31d6d97a801fe996b2f4aa5b99cdc159f3a7a403533e2ccf191b9ab5afc8b7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.","category":"company","datetime":1791554280,"headline":"ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y"}, {"id":142764326,"url":"https://finnhub.io/api/news?id=68e22a1e8c5032190f9b214e0eae9f3f501a0c8427956fea9704f1ba554ec03b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"VEEV's strong second-quarter results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.","category":"company","datetime":1791553380,"headline":"Reasons to Hold Veeva Systems Stock in Your Portfolio for Now"}, {"id":142731270,"url":"https://finnhub.io/api/news?id=0ed26bf6f6557e216075fee1446eb87ec0145d618b7bdca734d0261dab7ded7b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"SNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.","category":"company","datetime":1791476280,"headline":"Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets"}, {"id":142730063,"url":"https://finnhub.io/api/news?id=b4ec400d9af121f4582219f4a15c82ddddc99f351205421252b72488151aa5e5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.","category":"company","datetime":1791465000,"headline":"Here's Why You Should Retain WAT Stock in Your Portfolio for Now"}, {"id":142720710,"url":"https://finnhub.io/api/news?id=ce38488e0b79ff56fffbc495e662a29ddeb19bfec01bcbda355420552e85f3ee","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 29, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.","category":"company","datetime":1791453600,"headline":"West to Host Third-Quarter 2026 Conference Call"}, {"id":142714392,"url":"https://finnhub.io/api/news?id=934c43db3660d722a7b061f0cbe99e6a20e0bcbf7214dfc20f0bd48fb0f751cd","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2223220663/image_2223220663.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"WST","summary":"West Pharmaceutical's sustained premium valuation demands proven earnings and cash flow improvements. See why I rate WST stock a Sell.","category":"company","datetime":1791430532,"headline":"West Pharmaceutical Services Needs Faster Earnings Growth To Justify Its Price"}, {"id":142704930,"url":"https://finnhub.io/api/news?id=396ce0c5d19d15c2565049240f584d084b0c576b95a0294c7aeb9e87bd960d54","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services has seen its share price climb sharply in recent periods, and that kind of run naturally raises a question for anyone looking at the stock today: Are the cash flows the business can generate over time enough to support where the market is currently pricing West Pharmaceutical Services? The share price has gained 37.2% over the past year, which puts a lot of weight on whether the underlying cash flows can keep backing up that move. The group’s role in supplying...","category":"company","datetime":1791418604,"headline":"West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short"}, {"id":142699496,"url":"https://finnhub.io/api/news?id=4fd1462e14a8068f02509fa6e0bf57b9d5e275828a8087a408491600e48ee514","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.","category":"company","datetime":1791394560,"headline":"Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now"}, {"id":142697379,"url":"https://finnhub.io/api/news?id=266263d4bfc20da1cb9955c2d0af33b34d4339b28101d2e24e48433fa6b87667","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.","category":"company","datetime":1791384900,"headline":"BDX Expands U.S. Manufacturing With $19B Healthcare Investment"}, {"id":142697454,"url":"https://finnhub.io/api/news?id=82860d333e7b51aca61c43109ea92375bd0114d9fdd5bc30cc15ed3f20d662ac","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"HQY's strong HSA growth, AI-driven efficiencies and raised fiscal 2027 outlook support momentum, though cybersecurity risks remain a concern.","category":"company","datetime":1791378660,"headline":"Reasons to Hold HealthEquity Stock in Your Portfolio for Now"}, {"id":142695123,"url":"https://finnhub.io/api/news?id=040aecaeea9325c51813bff478015ff17a57404aa669f2cba2554f5cded4bba7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"VEEV's DQS cleans clinical trial data for over 1 million subjects across 1,000+ studies, expanding automation in clinical data management.","category":"company","datetime":1791377520,"headline":"Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies"}, {"id":142727972,"url":"https://finnhub.io/api/news?id=e3b6dec0384e187508c1598eef15ccc08785eec9409efff4382a99a5292b8e99","image":"","source":"Benzinga","related":"WST","summary":"Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $400 to $440.","category":"company","datetime":1791373126,"headline":"Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440"}, {"id":142692942,"url":"https://finnhub.io/api/news?id=276a8dfb6c0bab043b0f94c2eae815f8c2a8f78cda2fbe93acc8cb6978badaba","image":"https://media.gettyimages.com/id/2241146316/photo/close-up-of-medical-injector-on-conveyor-line-during-production-process-at-modern.jpg?b=1&s=612x612&w=0&k=20&c=xbyfAI2IEcrXsl5XxWEuMVC4MTnSwVmfug3U3nwtNWc=","source":"SeekingAlpha","related":"WST","summary":"West Pharma (WST) is still a buy: GLP-1 demand, HVP upgrades, and Annex 1 regulatory conversions fuel growth. Read here for a detailed analysis.","category":"company","datetime":1791358207,"headline":"West Pharma: Still A Buy, But Expectations Are Rising"}, {"id":142665889,"url":"https://finnhub.io/api/news?id=1d30f73b84317f4951cbffde765d910098122ab8de9b10373e2938e05df84596","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"MMSI's broad product portfolio, global expansion and strategic M&A support growth, while tariffs and China pressures remain key risks.","category":"company","datetime":1791296220,"headline":"Here's Why You Should Add Merit Medical Stock to Your Portfolio Now"}, {"id":142665886,"url":"https://finnhub.io/api/news?id=71d46b22fa6d97835fd0e16e258d3baec9c63b81fc3ace4de02afc7c5abd569d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"GEHC's $945M SOFIE Biosciences deal will expand its U.S. PET radiopharmaceutical footprint and boost exposure to precision care growth.","category":"company","datetime":1791296100,"headline":"GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal"}, {"id":142665841,"url":"https://finnhub.io/api/news?id=7684ab149c75a6611241a6e241b1447bfb4abc3df76fac2245282768a6c23163","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"CAH enters fiscal 2027 with Pharma profit growth, emerging growth engines and efficiency gains offsetting revenue headwinds.","category":"company","datetime":1791294240,"headline":"Reasons to Retain Cardinal Health Stock in Your Portfolio for Now"}, {"id":142637944,"url":"https://finnhub.io/api/news?id=3225700f0000186448e0c48a8bcfc72bf29c6dbd189622c3e4101d0032e609ca","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"DOCS' rapid clinical AI adoption and strong cash generation support its outlook, but tight pharma budgets and AI costs may limit near-term gains.","category":"company","datetime":1791212760,"headline":"Reasons to Retain Doximity Stock in Your Portfolio for Now"}, {"id":142637260,"url":"https://finnhub.io/api/news?id=216b3e60a44c986014f03b75bac5ad080205b157548e71f937d483dbf25099e8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"VEEV's OpenData deal with Servier across 80+ countries strengthens its Data Cloud role as life sciences firms scale AI and advanced analytics.","category":"company","datetime":1791212160,"headline":"Veeva's OpenData to Help Servier Build a Global AI Data Foundation"}, {"id":142636954,"url":"https://finnhub.io/api/news?id=1f77c39883a9badee4aa990a5a3ba091bade1d44a2219c6b9579dcec43b2ea63","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"INSP gains new Category I CPT codes for Inspire V procedures, creating a dedicated coding framework effective Jan. 1, 2028.","category":"company","datetime":1791211920,"headline":"Inspire Medical Gains New CPT Codes for Hypoglossal Nerve Stimulation"}, {"id":142637943,"url":"https://finnhub.io/api/news?id=f01435598b72cb037c02282b97ed1dded7390ba1ba3d381a6e160139cb4c981a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services will release its third-quarter earnings soon, and analysts anticipate a low double-digit bottom-line growth.","category":"company","datetime":1791199301,"headline":"What to Expect From West Pharmaceutical Services' Next Quarterly Earnings Report"}, {"id":142633169,"url":"https://finnhub.io/api/news?id=dc33fe661d7c2c3492f14647b52b156ae627758638cd09a354c63940fe379d75","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced its participation in CPHI Worldwide in Milan, Italy, where it will highlight its leadership and expertise in addressing industry challenges.","category":"company","datetime":1791194400,"headline":"West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide"}, {"id":142631137,"url":"https://finnhub.io/api/news?id=260b9b916255acd521ef0477decef09d37087460a3eb5277e2f8edb1bfb44ddb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.","category":"company","datetime":1791189780,"headline":"1 Cash-Producing Stock on Our Buy List and 2 Facing Challenges"}, {"id":142563086,"url":"https://finnhub.io/api/news?id=9fe356bb8b6c323b81461cdff686ec1dca817daefb117d2d9a070c3e2998bf36","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at West Pharmaceutical Services (NYSE:WST) and the best and worst performers in the drug development inputs & services industry.","category":"company","datetime":1790884627,"headline":"Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)"}, {"id":142765025,"url":"https://finnhub.io/api/news?id=6f3b40d9ecb8b2f445bc3546fe3407cec280820da805bba4bc1a2509006e1632","image":"https://image.cnbcfm.com/api/v1/image/108371167-1790873083887-1790872950-48726431161-hd.jpg?v=1790873085&w=1920&h=1080","source":"CNBC","related":"WST","summary":"Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's \"Halftime Report\" to spotlight West Pharmaceutical Services in his \"Best Stocks in the Market.\"","category":"company","datetime":1790858700,"headline":"Josh Brown's 'Best Stocks in the Market:' West Pharmaceutical Services"}, {"id":142522216,"url":"https://finnhub.io/api/news?id=90a057d79e8667db4d4ec9352646ed98e0292cae1df0b8ed83de6346aa944120","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"SNN expands its trauma portfolio with the EVOS PELVIC System, targeting complex pelvic and acetabular fracture procedures in the United States.","category":"company","datetime":1790787180,"headline":"Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care"}, {"id":142498423,"url":"https://finnhub.io/api/news?id=7064296f2ba9b30ab472588b5aec14b5e58d924cc5cd7bd7f0ea0eed807ad14c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"ITGR's $127-a-share KKR deal offers defined cash value, while core franchises face slow new-product adoption.","category":"company","datetime":1790690640,"headline":"Here's Why You Should Retain Integer Holdings Stock in Your Portfolio"}, {"id":142469358,"url":"https://finnhub.io/api/news?id=df6606a47f06bf41c262e3c74d80e5e1a9270c0e6b943a74aeee5a7d769eac3c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Becton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.","category":"company","datetime":1790608500,"headline":"Here's Why You Should Retain BDX Stock in Your Portfolio for Now"}, {"id":142453159,"url":"https://finnhub.io/api/news?id=a858de7c4755f727def1d938c4a395431e61d53c9193adecc8cfe68e25951e21","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260312486/image_2260312486.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"WST","summary":"The ProShares S&P 500 Dividend Aristocrats ETF trails SPY YTD, but 20 individual Aristocrats are outperforming the ETF. Check out the Aristocrats list here.","category":"company","datetime":1790556963,"headline":"Best Dividend Aristocrats For October 2026"}, {"id":142424949,"url":"https://finnhub.io/api/news?id=6dbd079c7174f0bb58e0ab95c6ace326965052422fd0cba48bd7af8b47011eb1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"VEEV's AI-powered Study Builder Agent automates clinical study setup, cutting manual work while strengthening its connected Clinical Data ecosystem.","category":"company","datetime":1790347980,"headline":"Veeva Unveils AI Study Builder Agent to Speed Clinical Trial Setup"}
data_source finnhub_news_keyword_model
article_count 2
negative_hits 0
positive_hits 1
recomputed_at_score true
sentiment_score_raw 1.2
source_article_count 39
discarded_article_count 37
sentimentPoints 6

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 3.2 5/110 64% 3.2
資金流 15.6 20/110 78% 15.6
市場環境 4.6 15/110 30.67% 4.6
催化劑 2 20/110 10% 2
風險管理 7.8 10/110 78% 7.8
技術信號 20.7 30/110 69% 20.7
情緒分析 6 10/110 60% 6

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 9/50
ret_5d 0.0212
max_score 50
max_total 50
raw_total 9
vcp_bonus 0
vol_ratio 1.4385
ret_points 4
vol_points 4
range_ratio 0.5127
volat_points 0
day_range_pct 0.0114
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 1
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.6

details

atrPct 2.1489
turnoverUsdM 281.5637
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.8

stopLevels

symbol US.WST
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 375.2958

strength_details

ma_score 1.5
atr_score 2
rsi_score 3
macd_score 3
volume_score 2
market_adjustment 1
risk_reward_ratio 1.7
stop_loss_percent 4.3
take_profit_price 421.1954
target_multiplier 2.2
technical_strength 2.35
take_profit_percent 7.4
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.7218
stopLossPercent 4.2979
diversificationPoints 2

Calculation audit log

基本面分析總分: 3.2/5分
資金流分析總分: 15.6/20分
市場環境分析總分: 4.6/15分
催化劑分析: 2/20分
風險管理總分: 7.8/10分
技術信號分析總分: 20.7/30分
情緒分析: 6/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 92.86
atr
atr 8.4271
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.15
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value 132.87
cmf
rule Cursor_18.24 CMF bands
level 平衡
score 4
value 0.086
kdj
d 82.76
j 94.73
k 86.75
rule Cursor_18.24 K/D cross
score 4
signal 金叉
mfi
rule Cursor_18.24 MFI bands
level 強資金流入
score 10
value 76.52
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 10
trend 強流入
value 3227900
recentSlope 264630
previousSlope -83590
rsi
value 66.6
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 371.4047
position SAR喺價下
distancePct 5.29
previousTrend 上升
ma50
value 362.0668
macd
macd 8.3164
trend 強烈看漲
signal 6.7207
histogram 1.5958
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 10
value 376.9416
position 連續5日>VWAP
consecutiveAbove 9
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.4
score 6
avgVolume 513335
currentVolume 718000
derived
ma20 376.582
ma50 362.0668
prevClose 394.03
avgVolume10 506520
avgVolume20 513335
changePercent -0.48
avgVolumeForScore 513335
ma_cross
ma20 376.582
ma50 362.0668
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 375.4965
prevMa50 361.147
spreadPct 4.01
isVolumeBreakout false
bollinger
lower 356.8398
upper 396.3242
position 上半部
rsi_short
value 84.82
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.4

Raw calculation JSON

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.148948161391002,
        "turnoverUsdM": 281.56369281999997,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.8,
    "stopLevels": {
      "symbol": "US.WST",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 375.2958,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.7,
      "stop_loss_percent": 4.3,
      "take_profit_price": 421.1954,
      "target_multiplier": 2.2,
      "technical_strength": 2.35,
      "take_profit_percent": 7.4
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.721772570635213,
    "stopLossPercent": 4.297896322782004,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 68.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 59.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 9
  },
  "market": {
    "ma20": 376.582,
    "ma50": 362.0668,
    "close": 392.15,
    "prevClose": 394.03,
    "avgVolume20": 513335,
    "volumeRatio": 1.4,
    "changePercent": -0.48
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 9,
    "details": {
      "ret_5d": 0.021170775566060396,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 9,
      "vcp_bonus": 0,
      "vol_ratio": 1.438488585252487,
      "ret_points": 4,
      "vol_points": 4,
      "range_ratio": 0.5126594254215875,
      "volat_points": 0,
      "day_range_pct": 0.011373173820557659,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 68.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 64,
        "contribution": 3.2
      },
      {
        "raw": 15.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 78,
        "contribution": 15.6
      },
      {
        "raw": 4.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 30.67,
        "contribution": 4.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 78,
        "contribution": 7.8
      },
      {
        "raw": 20.7,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 69,
        "contribution": 20.7
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 59.9,
    "details": [
      "基本面分析總分: 3.2/5分",
      "資金流分析總分: 15.6/20分",
      "市場環境分析總分: 4.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.8/10分",
      "技術信號分析總分: 20.7/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.2,
      "資金流": 15.6,
      "市場環境": 4.6,
      "情緒分析": 6,
      "技術信號": 20.7,
      "風險管理": 7.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 2,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "一般",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.6,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 281.56369281999997,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.WST",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 735.23500335,
                "ma50": 725.8121993399999,
                "name": "QQQ",
                "close": 704.40002,
                "points": 0.4
              },
              "spy": {
                "ma20": 770.1504974000001,
                "ma50": 767.8083956999998,
                "name": "SPY",
                "close": 759.96997,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.148948161391002,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 2,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142704930,
                "url": "https://finnhub.io/api/news?id=396ce0c5d19d15c2565049240f584d084b0c576b95a0294c7aeb9e87bd960d54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has seen its share price climb sharply in recent periods, and that kind of run naturally raises a question for anyone looking at the stock today: Are the cash flows the business can generate over time enough to support where the market is currently pricing West Pharmaceutical Services? The share price has gained 37.2% over the past year, which puts a lot of weight on whether the underlying cash flows can keep backing up that move. The group’s role in supplying...",
                "category": "company",
                "datetime": 1791418604,
                "headline": "West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short"
              },
              {
                "id": 142563086,
                "url": "https://finnhub.io/api/news?id=9fe356bb8b6c323b81461cdff686ec1dca817daefb117d2d9a070c3e2998bf36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at West Pharmaceutical Services (NYSE:WST) and the best and worst performers in the drug development inputs & services industry.",
                "category": "company",
                "datetime": 1790884627,
                "headline": "Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)"
              }
            ],
            "raw_source": [
              {
                "id": 143012560,
                "url": "https://finnhub.io/api/news?id=2ccb53addaa9d01eacfe7687646e84a97e6ee4cf6e4a9eac5b9b5469477a9e02",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "On October 19, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared a fourth-quarter dividend of $0.26 per share on the Company's common stock, an 18% increase over the $0.22 per share paid in the prior quarter. This is the thirty-fourth consecutive annual increase in the Company's dividend. The dividend is payable on November 18, 2026, to shareholders of record on November 11, 2026.",
                "category": "company",
                "datetime": 1792447440,
                "headline": "West Declares Quarterly Dividend"
              },
              {
                "id": 143025098,
                "url": "https://finnhub.io/api/news?id=184da90b2ecaa23ac41e65cf4a68ca4e56b6205b3de07c9de99399644af7a9b5",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/19/Monticello---Circa-June-2018-Ball-Corpor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "WST",
                "summary": "Ball Corp stock is on an 11-day winning streak, its longest since NYSE trading began in 1973, while the S&P 500 has slipped. Here is what the data shows.",
                "category": "company",
                "datetime": 1792422605,
                "headline": "This 146-Old Can Maker Is On a Winning Streak Unseen In Its Half-Century Stock History"
              },
              {
                "id": 143000911,
                "url": "https://finnhub.io/api/news?id=9f249892f67c2c347a5af48c3b7f211933f468a1f63145c7891bc123511d8112",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.",
                "category": "company",
                "datetime": 1792402615,
                "headline": "3 Low-Volatility Stocks We’re Skeptical Of"
              },
              {
                "id": 142916913,
                "url": "https://finnhub.io/api/news?id=e43427db7a051fa81b2854dcfd0b6bd24d6b41b26470c7092a985c1c34b6620a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical shares have surged 36.1% YTD, fueled by strong demand for high-value components, earnings momentum and raised guidance. Can the rally continue?",
                "category": "company",
                "datetime": 1792067100,
                "headline": "West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?"
              },
              {
                "id": 142883145,
                "url": "https://finnhub.io/api/news?id=cb38b4a6f60d1666f4829b94ca34f67fc98bf5704a46799c99024c3bf926f5dd",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/14/Experts-Stress-Individual-Strategy.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "WST",
                "summary": "CNBC traders picked WST, JPM, META and IYE; analysts raised WST and META targets, while JPM missed Q3 earnings and revenue estimates.",
                "category": "company",
                "datetime": 1791965393,
                "headline": "Meta, JPMorgan, West Pharmaceutical And More: CNBC’s ‘Final Trades’"
              },
              {
                "id": 142851461,
                "url": "https://finnhub.io/api/news?id=01a6d2c9516083848f4715e79557defa90311fe00d1d962ba8800ec121c82bee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "VEEV's push into early-stage biotech could unlock long-term revenue opportunities as its streamlined software solutions simplify critical drug development processes.",
                "category": "company",
                "datetime": 1791900180,
                "headline": "Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms"
              },
              {
                "id": 142852015,
                "url": "https://finnhub.io/api/news?id=5c93e86e39a831dabc1abec85f4b6dda5ce3762aebf201f5f36fbb96e9de0f04",
                "image": "https://image.cnbcfm.com/api/v1/image/108404206-17919110711791911068-48976902142-1080pnbcnews.jpg?v=1791911070&w=1920&h=1080",
                "source": "CNBC",
                "related": "WST",
                "summary": "The Investment Committee gives you their top stocks to watch for the second half.",
                "category": "company",
                "datetime": 1791897084,
                "headline": "Final Trades: JP Morgan, Meta, West Pharmaceutical Services and the iShares U.S. Energy ETF"
              },
              {
                "id": 140020268,
                "url": "https://finnhub.io/api/news?id=4f3164aa80c98143908bac684d9370239ee6fc0adb34291736a50ae401f2fc06",
                "image": "",
                "source": "Benzinga",
                "related": "WST",
                "summary": "",
                "category": "company",
                "datetime": 1791896442,
                "headline": "Inexpensive Stocks Found In This Sector"
              },
              {
                "id": 142883147,
                "url": "https://finnhub.io/api/news?id=64790aefb0dca839b96e5a83d13b90b9b8a6e2684e44515eb2c3a5b6bcb1f488",
                "image": "",
                "source": "Benzinga",
                "related": "WST",
                "summary": "TD Cowen  analyst Brendan Smith   maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $410 to $420.",
                "category": "company",
                "datetime": 1791895217,
                "headline": "TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $420"
              },
              {
                "id": 142806662,
                "url": "https://finnhub.io/api/news?id=88a74baf83fffd8b419bb6c42be37ea4daa59b2aa69282ceb6e60f787cf3393b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2252678669/image_2252678669.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "Track 50 top dividend growth stocks: AMAT, DHI & HD climb as valuations shift.",
                "category": "company",
                "datetime": 1791722816,
                "headline": "Top 50 High-Quality Dividend Growth Stocks For October 2026"
              },
              {
                "id": 142764350,
                "url": "https://finnhub.io/api/news?id=2e31d6d97a801fe996b2f4aa5b99cdc159f3a7a403533e2ccf191b9ab5afc8b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.",
                "category": "company",
                "datetime": 1791554280,
                "headline": "ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y"
              },
              {
                "id": 142764326,
                "url": "https://finnhub.io/api/news?id=68e22a1e8c5032190f9b214e0eae9f3f501a0c8427956fea9704f1ba554ec03b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "VEEV's strong second-quarter results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.",
                "category": "company",
                "datetime": 1791553380,
                "headline": "Reasons to Hold Veeva Systems Stock in Your Portfolio for Now"
              },
              {
                "id": 142731270,
                "url": "https://finnhub.io/api/news?id=0ed26bf6f6557e216075fee1446eb87ec0145d618b7bdca734d0261dab7ded7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "SNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.",
                "category": "company",
                "datetime": 1791476280,
                "headline": "Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets"
              },
              {
                "id": 142730063,
                "url": "https://finnhub.io/api/news?id=b4ec400d9af121f4582219f4a15c82ddddc99f351205421252b72488151aa5e5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.",
                "category": "company",
                "datetime": 1791465000,
                "headline": "Here's Why You Should Retain WAT Stock in Your Portfolio for Now"
              },
              {
                "id": 142720710,
                "url": "https://finnhub.io/api/news?id=ce38488e0b79ff56fffbc495e662a29ddeb19bfec01bcbda355420552e85f3ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 29, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.",
                "category": "company",
                "datetime": 1791453600,
                "headline": "West to Host Third-Quarter 2026 Conference Call"
              },
              {
                "id": 142714392,
                "url": "https://finnhub.io/api/news?id=934c43db3660d722a7b061f0cbe99e6a20e0bcbf7214dfc20f0bd48fb0f751cd",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2223220663/image_2223220663.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "West Pharmaceutical's sustained premium valuation demands proven earnings and cash flow improvements. See why I rate WST stock a Sell.",
                "category": "company",
                "datetime": 1791430532,
                "headline": "West Pharmaceutical Services Needs Faster Earnings Growth To Justify Its Price"
              },
              {
                "id": 142704930,
                "url": "https://finnhub.io/api/news?id=396ce0c5d19d15c2565049240f584d084b0c576b95a0294c7aeb9e87bd960d54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has seen its share price climb sharply in recent periods, and that kind of run naturally raises a question for anyone looking at the stock today: Are the cash flows the business can generate over time enough to support where the market is currently pricing West Pharmaceutical Services? The share price has gained 37.2% over the past year, which puts a lot of weight on whether the underlying cash flows can keep backing up that move. The group’s role in supplying...",
                "category": "company",
                "datetime": 1791418604,
                "headline": "West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short"
              },
              {
                "id": 142699496,
                "url": "https://finnhub.io/api/news?id=4fd1462e14a8068f02509fa6e0bf57b9d5e275828a8087a408491600e48ee514",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.",
                "category": "company",
                "datetime": 1791394560,
                "headline": "Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now"
              },
              {
                "id": 142697379,
                "url": "https://finnhub.io/api/news?id=266263d4bfc20da1cb9955c2d0af33b34d4339b28101d2e24e48433fa6b87667",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.",
                "category": "company",
                "datetime": 1791384900,
                "headline": "BDX Expands U.S. Manufacturing With $19B Healthcare Investment"
              },
              {
                "id": 142697454,
                "url": "https://finnhub.io/api/news?id=82860d333e7b51aca61c43109ea92375bd0114d9fdd5bc30cc15ed3f20d662ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "HQY's strong HSA growth, AI-driven efficiencies and raised fiscal 2027 outlook support momentum, though cybersecurity risks remain a concern.",
                "category": "company",
                "datetime": 1791378660,
                "headline": "Reasons to Hold HealthEquity Stock in Your Portfolio for Now"
              },
              {
                "id": 142695123,
                "url": "https://finnhub.io/api/news?id=040aecaeea9325c51813bff478015ff17a57404aa669f2cba2554f5cded4bba7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "VEEV's DQS cleans clinical trial data for over 1 million subjects across 1,000+ studies, expanding automation in clinical data management.",
                "category": "company",
                "datetime": 1791377520,
                "headline": "Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies"
              },
              {
                "id": 142727972,
                "url": "https://finnhub.io/api/news?id=e3b6dec0384e187508c1598eef15ccc08785eec9409efff4382a99a5292b8e99",
                "image": "",
                "source": "Benzinga",
                "related": "WST",
                "summary": "Barclays  analyst Luke Sergott   maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $400 to $440.",
                "category": "company",
                "datetime": 1791373126,
                "headline": "Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440"
              },
              {
                "id": 142692942,
                "url": "https://finnhub.io/api/news?id=276a8dfb6c0bab043b0f94c2eae815f8c2a8f78cda2fbe93acc8cb6978badaba",
                "image": "https://media.gettyimages.com/id/2241146316/photo/close-up-of-medical-injector-on-conveyor-line-during-production-process-at-modern.jpg?b=1&s=612x612&w=0&k=20&c=xbyfAI2IEcrXsl5XxWEuMVC4MTnSwVmfug3U3nwtNWc=",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "West Pharma (WST) is still a buy: GLP-1 demand, HVP upgrades, and Annex 1 regulatory conversions fuel growth. Read here for a detailed analysis.",
                "category": "company",
                "datetime": 1791358207,
                "headline": "West Pharma: Still A Buy, But Expectations Are Rising"
              },
              {
                "id": 142665889,
                "url": "https://finnhub.io/api/news?id=1d30f73b84317f4951cbffde765d910098122ab8de9b10373e2938e05df84596",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "MMSI's broad product portfolio, global expansion and strategic M&A support growth, while tariffs and China pressures remain key risks.",
                "category": "company",
                "datetime": 1791296220,
                "headline": "Here's Why You Should Add Merit Medical Stock to Your Portfolio Now"
              },
              {
                "id": 142665886,
                "url": "https://finnhub.io/api/news?id=71d46b22fa6d97835fd0e16e258d3baec9c63b81fc3ace4de02afc7c5abd569d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "GEHC's $945M SOFIE Biosciences deal will expand its U.S. PET radiopharmaceutical footprint and boost exposure to precision care growth.",
                "category": "company",
                "datetime": 1791296100,
                "headline": "GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal"
              },
              {
                "id": 142665841,
                "url": "https://finnhub.io/api/news?id=7684ab149c75a6611241a6e241b1447bfb4abc3df76fac2245282768a6c23163",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "CAH enters fiscal 2027 with Pharma profit growth, emerging growth engines and efficiency gains offsetting revenue headwinds.",
                "category": "company",
                "datetime": 1791294240,
                "headline": "Reasons to Retain Cardinal Health Stock in Your Portfolio for Now"
              },
              {
                "id": 142637944,
                "url": "https://finnhub.io/api/news?id=3225700f0000186448e0c48a8bcfc72bf29c6dbd189622c3e4101d0032e609ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "DOCS' rapid clinical AI adoption and strong cash generation support its outlook, but tight pharma budgets and AI costs may limit near-term gains.",
                "category": "company",
                "datetime": 1791212760,
                "headline": "Reasons to Retain Doximity Stock in Your Portfolio for Now"
              },
              {
                "id": 142637260,
                "url": "https://finnhub.io/api/news?id=216b3e60a44c986014f03b75bac5ad080205b157548e71f937d483dbf25099e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "VEEV's OpenData deal with Servier across 80+ countries strengthens its Data Cloud role as life sciences firms scale AI and advanced analytics.",
                "category": "company",
                "datetime": 1791212160,
                "headline": "Veeva's OpenData to Help Servier Build a Global AI Data Foundation"
              },
              {
                "id": 142636954,
                "url": "https://finnhub.io/api/news?id=1f77c39883a9badee4aa990a5a3ba091bade1d44a2219c6b9579dcec43b2ea63",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "INSP gains new Category I CPT codes for Inspire V procedures, creating a dedicated coding framework effective Jan. 1, 2028.",
                "category": "company",
                "datetime": 1791211920,
                "headline": "Inspire Medical Gains New CPT Codes for Hypoglossal Nerve Stimulation"
              },
              {
                "id": 142637943,
                "url": "https://finnhub.io/api/news?id=f01435598b72cb037c02282b97ed1dded7390ba1ba3d381a6e160139cb4c981a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services will release its third-quarter earnings soon, and analysts anticipate a low double-digit bottom-line growth.",
                "category": "company",
                "datetime": 1791199301,
                "headline": "What to Expect From West Pharmaceutical Services' Next Quarterly Earnings Report"
              },
              {
                "id": 142633169,
                "url": "https://finnhub.io/api/news?id=dc33fe661d7c2c3492f14647b52b156ae627758638cd09a354c63940fe379d75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced its participation in CPHI Worldwide in Milan, Italy, where it will highlight its leadership and expertise in addressing industry challenges.",
                "category": "company",
                "datetime": 1791194400,
                "headline": "West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide"
              },
              {
                "id": 142631137,
                "url": "https://finnhub.io/api/news?id=260b9b916255acd521ef0477decef09d37087460a3eb5277e2f8edb1bfb44ddb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
                "category": "company",
                "datetime": 1791189780,
                "headline": "1 Cash-Producing Stock on Our Buy List and 2 Facing Challenges"
              },
              {
                "id": 142563086,
                "url": "https://finnhub.io/api/news?id=9fe356bb8b6c323b81461cdff686ec1dca817daefb117d2d9a070c3e2998bf36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at West Pharmaceutical Services (NYSE:WST) and the best and worst performers in the drug development inputs & services industry.",
                "category": "company",
                "datetime": 1790884627,
                "headline": "Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)"
              },
              {
                "id": 142765025,
                "url": "https://finnhub.io/api/news?id=6f3b40d9ecb8b2f445bc3546fe3407cec280820da805bba4bc1a2509006e1632",
                "image": "https://image.cnbcfm.com/api/v1/image/108371167-1790873083887-1790872950-48726431161-hd.jpg?v=1790873085&w=1920&h=1080",
                "source": "CNBC",
                "related": "WST",
                "summary": "Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's \"Halftime Report\" to spotlight West Pharmaceutical Services in his \"Best Stocks in the Market.\"",
                "category": "company",
                "datetime": 1790858700,
                "headline": "Josh Brown's 'Best Stocks in the Market:' West Pharmaceutical Services"
              },
              {
                "id": 142522216,
                "url": "https://finnhub.io/api/news?id=90a057d79e8667db4d4ec9352646ed98e0292cae1df0b8ed83de6346aa944120",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "SNN expands its trauma portfolio with the EVOS PELVIC System, targeting complex pelvic and acetabular fracture procedures in the United States.",
                "category": "company",
                "datetime": 1790787180,
                "headline": "Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care"
              },
              {
                "id": 142498423,
                "url": "https://finnhub.io/api/news?id=7064296f2ba9b30ab472588b5aec14b5e58d924cc5cd7bd7f0ea0eed807ad14c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "ITGR's $127-a-share KKR deal offers defined cash value, while core franchises face slow new-product adoption.",
                "category": "company",
                "datetime": 1790690640,
                "headline": "Here's Why You Should Retain Integer Holdings Stock in Your Portfolio"
              },
              {
                "id": 142469358,
                "url": "https://finnhub.io/api/news?id=df6606a47f06bf41c262e3c74d80e5e1a9270c0e6b943a74aeee5a7d769eac3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Becton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.",
                "category": "company",
                "datetime": 1790608500,
                "headline": "Here's Why You Should Retain BDX Stock in Your Portfolio for Now"
              },
              {
                "id": 142453159,
                "url": "https://finnhub.io/api/news?id=a858de7c4755f727def1d938c4a395431e61d53c9193adecc8cfe68e25951e21",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260312486/image_2260312486.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "The ProShares S&P 500 Dividend Aristocrats ETF trails SPY YTD, but 20 individual Aristocrats are outperforming the ETF. Check out the Aristocrats list here.",
                "category": "company",
                "datetime": 1790556963,
                "headline": "Best Dividend Aristocrats For October 2026"
              },
              {
                "id": 142424949,
                "url": "https://finnhub.io/api/news?id=6dbd079c7174f0bb58e0ab95c6ace326965052422fd0cba48bd7af8b47011eb1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "VEEV's AI-powered Study Builder Agent automates clinical study setup, cutting manual work while strengthening its connected Clinical Data ecosystem.",
                "category": "company",
                "datetime": 1790347980,
                "headline": "Veeva Unveils AI Study Builder Agent to Speed Clinical Trial Setup"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 2,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 39,
            "discarded_article_count": 37
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.7,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.4,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.4,
            "vcp_reason": "站上MA50;Ready=N;Confirm=N",
            "vcp_metrics": {
              "up_days": 8,
              "vol_ref": 583796.6666666666,
              "down_days": 1,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 482740,
              "avg_vol_20": 499135,
              "avg_vol_30": 583796.6666666666,
              "range_pct_10": 0.08920058878491888,
              "range_pct_20": 0.09606020900319301,
              "range_pct_30": 0.14147650494648756,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8268974928485375,
              "dist_to_20d_high": 0.012614588578910318,
              "down_shrink_days": 1,
              "breakout_level_20d": 397.16,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6304975431691526
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 3.2,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.148948161391002,
              "turnoverUsdM": 281.56369281999997,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.8,
          "stopLevels": {
            "symbol": "US.WST",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 375.2958,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.7,
            "stop_loss_percent": 4.3,
            "take_profit_price": 421.1954,
            "target_multiplier": 2.2,
            "technical_strength": 2.35,
            "take_profit_percent": 7.4
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.721772570635213,
          "stopLossPercent": 4.297896322782004,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.WST",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 8.4271,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.15
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 132.87
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.086
    },
    "kdj": {
      "d": 82.76,
      "j": 94.73,
      "k": 86.75,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 76.52
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 3227900,
      "recentSlope": 264630,
      "previousSlope": -83590
    },
    "rsi": 66.6,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 371.4047,
      "position": "SAR喺價下",
      "distancePct": 5.29,
      "previousTrend": "上升"
    },
    "ma50": 362.0668,
    "macd": {
      "macd": 8.316435651077995,
      "trend": "強烈看漲",
      "signal": 6.7206778619611764,
      "histogram": 1.5957577891168189
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 376.9416,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 9
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.4,
      "score": 6,
      "avgVolume": 513335,
      "currentVolume": 718000
    },
    "derived": {
      "ma20": 376.582,
      "ma50": 362.0668,
      "prevClose": 394.03,
      "avgVolume10": 506520,
      "avgVolume20": 513335,
      "changePercent": -0.48,
      "avgVolumeForScore": 513335
    },
    "ma_cross": {
      "ma20": 376.582,
      "ma50": 362.0668,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 375.4965,
      "prevMa50": 361.147,
      "spreadPct": 4.01,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 356.8398,
      "upper": 396.3242,
      "position": "上半部"
    },
    "rsi_short": 84.82,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.4
    }
  }
}

Raw metrics JSON

{
  "close": 392.15,
  "volume": 718000,
  "changePercent": -0.48
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.